Study how people resist azacitidine in blood cancers
Part of Blood & lymphatic clinical trials.
This study looks at why some people with higher-risk blood cancers (MDS/AML-MD) do not respond as well to azacitidine. The goal is to learn the causes of resistance so future treatments may work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have a diagnosis of high-risk or intermediate-2 MDS, or AML-MD
- Your doctor says your MDS/AML type matches the study’s specific classifications
- You must have already taken azacitidine for at least 3 to 6 treatment cycles
- You must be willing to sign an informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how certain enzymes in your body affect the way a drug called azacytidine works against blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The goal is to better understand who might benefit most from this treatment.
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
This study looks at how leukemia cells become resistant to two common drug combinations: azacitidine plus venetoclax or azacitidine plus ivosidenib. It is for people with newly diagnosed AML who are about to start one of these treatments.
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
Hear when a new Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.